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Abstract
Background: There is increasing evidence linking vitamin D deficiency to both susceptibility to, and severity of,
multiple sclerosis (MS). Patients with the clinically isolated syndrome represent the initial presentation of a
demyelinating disorder, and those with asymptomatic lesions on magnetic resonance imaging (MRI) are at risk of
progression to clinically definite MS. The aims of this study are to examine the immunologic effects of vitamin D in
both healthy individuals and in patients with clinically isolated syndrome, and in the latter group the effects on
disease progression assessed by MRI and clinical measures.
Methods/Design: This is a single-center double-blind randomized placebo-controlled clinical trial. The primary
endpoint is the immunologic effects of two doses of vitamin D compared with placebo over 24 weeks in both
healthy control participants and patients presenting with the clinically isolated syndrome. Healthy control
participants (n = 39) and patients with clinically isolated syndrome (n = 45) will be randomized to one of three
arms, namely 1) vitamin D 5,000 IU daily, 2) vitamin D 10,000 IU daily, or 3) placebo, and followed up for 24 weeks.
In both patients and healthy control participants, the primary outcome will be immunologic measures of the
frequency of CD4 T-cell subsets and cytokine responses in peripheral blood mononuclear cells, assessed at baseline,
and after 16 and 24 weeks of treatment. Secondary endpoints, in the patients with clinically isolated syndrome, will
be relapse activity, and the number of new T2 lesions and gadolinium-enhancing lesions assessed by MRI in the
two vitamin D-treated groups compared with the placebo-treated group over the 24 weeks of the study.
Trial registration: EU Clinical Trials Register: EudraCT: 2012-000635-68. ClinicalTrials.gov identifier: NCT01728922
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Background
Multiple sclerosis (MS), a chronic inflammatory disease
of the central nervous system, is the most common dis-
abling neurologic disorder of young adults. The causes
of MS remain unknown, but it is widely believed that
there is interplay between genetic and environmental
factors [1]. Evidence for the role of the environment in
the development of MS is supported by a strong correl-
ation between MS incidence/prevalence and increased
latitude and lower levels of sun exposure, suggesting an
association with vitamin D production [2-4]. Individ-
uals who emigrate before the age of 15 years from an
area of high MS prevalence to one of low prevalence,
acquire the lower risk of MS in their new country of
residence. Migration studies provide perhaps the stron-
gest support for the role of environmental factor(s) in
this disease [5,6].
People living at high latitudes are generally deficient in
vitamin D, as measured by serum 25-hydroxyvitamin D
(25(OH)D) levels [7,8]. In one study, mean winter 25
(OH)D levels in healthy control subjects in Ireland were
36.4 nmol/l, and more patients with MS had vitamin D
deficiency (serum 25(OH)D levels less than 25 nmol/l)
compared with control subjects [9]. Patients have lower
serum vitamin D levels during MS relapses, and also
have blunted parathyroid hormone responses [10,11]. In
267 Dutch patients with relapsing remitting multiple
sclerosis (RRMS), higher vitamin D levels were associ-
ated with an increased chance of remaining relapse-free
[11]. In 134 North American patients with RRMS or
clinically isolated syndrome (CIS) of pediatric onset, the
strongest predictor of further relapse was the baseline
serum vitamin D level [12]. In a prospective Australian
study of 145 patients with RRMS, each increase of 10
nmol/l in baseline serum vitamin D level was associated
with a 12% reduction in the risk of a further relapse
[13]. Vitamin D deficiency may increase susceptibility to
MS even in utero; higher maternal vitamin D intake dur-
ing pregnancy was associated with a 38% lower risk of
MS in offspring [14], and maternal vitamin D levels greater
than 75 nmol/l were associated with a 61% reduced risk of
MS in children [15]. Month of birth studies showing an in-
creased MS incidence in those with spring versus autumn
births also provide evidence of the role of maternal
vitamin D [16].
The potential therapeutic effect of vitamin D supple-
mentation was first suggested by Goldberg in 1986 [17].
Dosing studies in healthy volunteers have shown that
supplementation with vitamin D 10,000 IU daily results
in an increase in serum 25(OH)D levels of 150 nmol/l
over a 12 week period [18]. A Canadian phase I/II open-
label, randomized, placebo-controlled trial (RCT) of
49 patients with RRMS who were randomized to
placebo or escalating doses of vitamin D over a 52
week period showed a trend toward relapse reduction in
the actively treated group [19]. This study was primarily
aimed at establishing the safety and tolerability of high-
dose vitamin D supplementation; the mean vitamin D
dose was 14,000 IU per day, and there were no adverse
events or hypercalcamia despite maximum mean vitamin
D levels of 413 nmol/l being achieved. The results from
this phase II trial [19], and from dosing [18] and obser-
vational studies [12,13], suggest that pharmacologic
doses of vitamin D of up to 10,000 IU/day are safe, and
may reduce the risk of relapse by a factor superior to
the 30% reduction reported from the pivotal trials of
interferons in RRMS [20,21].
Vitamin D modulates both the innate and adaptive
immune systems [22]. The active metabolite, 1,25 (OH)
vitamin D, primarily mediates its effects through the
intracellular vitamin D receptor (VDR) [23], which is
present in monocytes, dendritic cells, B-cells, and CD4+
T-cells [11,22]. Activation of VDR alters transcription,
proliferation, and differentiation of immune cells [23],
and modulates immune response both indirectly, by
reducing the activation of pro-inflammatory T-cells by
antigen-presenting cells [24], and directly, by inhibiting
T-cell and B-cell proliferation [22,25]. This results in
a T-helper (Th) 2-cell driven anti-inflammatory state
[11,22,26].
There is thus accumulating evidence that vitamin D
deficiency increases susceptibility to MS, and that vita-
min D supplementation reduces disease activity by im-
munomodulatory mechanisms. It seems probable that
serum vitamin D levels of greater than 100 nmol/l are
required to produce the immunologic effects of vitamin
D and thus, in patients with MS with vitamin D defi-
ciency, doses of 5,000 to 10,000 IU/day are needed to
achieve this. Most patients with RRMS, once diagnosed,
commence treatment with first-line disease-modifying
therapies (DMTs). Several RCTs are underway to exam-
ine the effects of vitamin D supplementation in patients
with RRMS already receiving first-line DMTs, using clin-
ical and MRI outcomes [27,28]. In the UK and Ireland,
patients with CIS are not usually commenced on DMTs
until there is clinical or MRI evidence of dissemination
in time. These CIS patients, at risk of developing RRMS,
may be recruited into trials of potentially therapeutic
agents in order to examine the efficacy of specific ther-
apies in preventing the development of clinically definite
MS [29]. We have therefore designed this RCT to exam-
ine, over a 24 week treatment period the effects on im-
munologic measures as a primary outcome, both in
patients with CIS and in healthy control participants,
randomized to either of two doses of vitamin D (5,000
or 10,000 IU) or to placebo. In addition, in the patients
with CIS, clinical and MRI efficacy measures will be
assessed as secondary outcomes.




This is a single-center investigator-led, phase II, explora-
tory, double-blind, dose-ranging, randomized, placebo-
controlled trial to assess the immune responses to two
doses of vitamin D in patients with CIS and in healthy
control participants. Recruitment commenced in November
2012. In total, 45 patients with CIS and 39 healthy control
participants will be enrolled and randomized to one of
three arms, placebo oil or vitamin D oil (Vigantol®; Merck
Serono, Darmstadt, Germany) at a dose of 5,000 IU or
10,000 IU, all of which will be taken orally for a period of
24 weeks.
Ethics
Ethical approval has been granted by St Vincent’s Hos-
pital Ethics and Medical Research Committee, and the
study has been approved by the Irish Medicines Board.
The study will comply with the ethical principles as set
down in the Declaration of Helsinki, and will be
conducted in accordance with good clinical practice as
defined by the International Conference on Harmonisa-
tion (ICH). The trial is registered with ClinicalTrials.gov
NCT01728922 and EU Clinical Trials Register EudraCT
number 2012-000635-68.
Study participants
Study participants will be composed of two groups: 1)
45 patients with CIS, and 2) 39 healthy control par-
ticipants.
Inclusion criteria
1) Patients with CIS aged between 18 and 55 years will
be eligible for entry into the study if symptom onset
occurred within 3 months of screening, they have
two or more asymptomatic T2 lesions on MRI brain
consistent with demyelination, not treated with
steroids within 30 days of screening and are not on
any other DMT.
2) Healthy control participants will be recruited from
hospital staff, and will be aged between 20 and 40 years
with a female:male ratio of 2:1, in line with the gender
ratio seen with CIS.
Exclusion criteria
Exclusion criteria both for patients with CIS and for
healthy control participants include: no history or evi-
dence of hypercalcemia, renal impairment, vitamin D in-
tolerance, parathyroid dysfunction, sarcoidosis, prior or
current treatment with thiazide diuretics, or vitamin D
supplementation of greater than 1,000 IU/day. Exclusion
criteria for patients with CIS include: 1) if their symp-
toms might be explained by another diagnosis other than
MS; 2) occurrence of an exacerbation less than 6 weeks
prior to study entry; 3) previous treatment with β-
interferons or glatiramer acetate in the 3 months before
study entry, previous treatment with steroids in the 4
weeks before study entry, or any previous treatment with
mitoxantrone or other immunosuppressant; and d) con-
current enrolment in any other clinical trial investigating
DMT in CIS.
All female patients and healthy controls will be advised
not to become pregnant for the duration of the study,
and if sexually active to use effective contraception for
the duration of the study and for 3 months after.
Randomization
Patients with CIS and healthy control participants who
fulfill the inclusion criteria will be enrolled in the study
after providing informed consent at the screening visit.
At the baseline visit, study participants who remain eli-
gible will be assigned a number in ascending order: 1 to
45 for the CIS group and 1 to 39 for controls. The CIS
group will be denoted by an X before this number, and
the controls a Y. These numbers were randomized using
the software program GraphPad [30] by the hospital
pharmacist. The healthy control participants and pa-
tients with CIS will be randomized separately to main-




The active therapy is vitamin D. The active principle will
be cholecalciferol in the form of an oil (Vigantol Oil®;
Merck Serono, Darmstadt, Germany), which is biologically
inactive and is a precursor for the metabolically active
metabolite calcitriol (1,25(OH)2D3).
Placebo therapy
A placebo oil, not containing vitamin D but identical to
the active principle in all other respects, will be used.
Dispensing
Both the active and placebo oils will be dispensed in bottles
with droppers, which contain 10 ml of fluid, with 20,000 IU
of cholecalciferol per ml.
Study endpoints
The primary endpoint is the effect of oral vitamin D at
5,000 and 10,000 IU/day compared with placebo on the
frequency of CD4 T-cell subsets and cytokine responses
in peripheral blood mononuclear cells in patients with
CIS and in healthy control participants at weeks 16 and
24 compared with baseline.
Secondary endpoints include: the following. 1) In the
patients with CIS having MRI brain scans at baseline
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and week 24, the number of new and enlarging T2
lesions and gadolinium-enhancing lesions at week 24
compared with baseline in patients receiving oral vita-
min D at 5000 IU and 10,000 IU/ day compared with
placebo, 2) In the patients with CIS, the effects of oral
vitamin D at 5,000 and 10,000 IU/day compared with
placebo on relapse occurrence, calculated as the annual-
ized relapse rate (ARR), the percentage of patients who
are relapse-free, and time to first relapse. 3) The effects
of oral vitamin D at 5,000 and 10,000 IU/day compared
with placebo on the percentage of treated patients with
CIS who are free from any evidence of disease (clinical
and MRI) activity.
Study visits and outcome parameters
Participants will be screened following discussion of the
trial and provision of signed, fully informed consent. If
the participants satisfy the inclusion criteria at screening,
they will then be scheduled for a baseline visit. The
study scheme is outlined in Figure 1. There will be
follow-up visits scheduled every 4 weeks visits until the
end of study visit at week 24, and a safety visit at week
28 will also be arranged.
At all visits, study participants will have any changes
in medical history or medications recorded, and will
undergo a general physical and neurologic examination.
Patients with CIS will be assessed for any evidence of
relapse, defined as the appearance of a new neurologic
abnormality or reappearance of a previously seen neuro-
logic abnormality, separated by at least 30 days from the
onset of the preceding event. The abnormality must be
present for at least 24 hours, must be based on objective
clinical evidence, and must occur in the absence of fever
or known infection.
Blood biochemistry, including liver function tests,
electrolytes, urea, creatinine, and serum calcium will be
measured at all study visits.
Serum vitamin D levels and parathormone levels will
be assessed at baseline, and at weeks 4, 8, 12, 16 and 24.
Serum 25(OH)D levels will be measured by liquid
chromatography-mass spectrometry. Intact parathor-
mone levels will be measured by a two-step sandwich
immunoassay using chemiluminescence technology.
Immunologic analysis will be carried out at baseline,
and at weeks 16 and 24. Peripheral blood mononuclear
cells (PBMCs) will be isolated within 12 hours of draw-
ing blood, and cryopreserved until samples from all
three time points have been collected. Cytokine produc-
tion will be measured by ELISA, and will include 1)
cytokine production by T cells and by other cells such as
monocytes, and 2) flow cytometry, gating specifically on
CD4 and CD8 T cells. 1) For analysis of PBMC cytokine
production, PBMCs from each timepoint will be thawed
out and stimulated with antigen (purified protein deriva-
tive (PPD) and tetanus toxoid) or polyclonal stimuli
(anti-CD3 and phytohaemaglutinin). After 3 to 5 days
(for polyclonal or antigen-specific stimulation respect-
ively), the cell culture supernatants will be assayed by
Figure 1 Schematic diagram of study structure. There are two study groups of subjects: 39 healthy control participants and 45 patients with
clinically isolated syndrome (CIS). Each of the two groups will be randomly allocated to one of three blinded treatments: placebo, vitamin D 5,000 IU,
or vitamin D 10,000 IU daily. Study duration is 24 weeks with immunologic testing (primary endpoint) of all study participants at baseline, week 16,
and week 24. There will be 4-weekly clinic visits to assess safety measures and clinical status. 4 weeks after completion of the study there will be a
follow-up safety visit. Magnetic resonance imaging will be carried out at baseline and week 24 in the CIS population only.
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ELISA for cytokines including interleukin (IL)-10 and
IL-17, and interferon (IFN)-γ. 1) For flow cytometry ana-
lysis of T-cell subsets, stimulated PBMCs from experi-
ment 1, will be re-stimulated on day 5 with PMA and
ionomycin in the presence of brefeldin A for 5 hours,
followed by cell surface staining for T-cell markers
(CD3, CD8) and intracellular staining for cytokines in-
cluding IL-10, IL-17, and IFN-γ. The cells will be acquired
on a FACSCanto II flow cytometer (Becton Dickinson),
and analyzed using FlowJo software. Cytokine production
by CD3+ CD8− (CD4 T-cells) and CD3+ CD8+ (CD8
T-cells) will be analyzed.
MRI scanning at baseline visit and week 24
Brain MRI will be performed with contiguous axial 3 mm
thick slices. Sequences will include axial and coronal T1-
weighted spin echo (before and after gadolinium contrast
enhancement), axial and sagittal PD/T2-weighted, and
axial fast fluid attenuated inversion recovery, before
contrast. MRI assessment will include 1) number of
gadolinium enhancing lesions, 2) number of new and
enlarging T2 lesions, and 3) the total number of new
lesions (the sum of 1) and 2)).
An enhancing new T2 lesion will be considered a
single lesion. Two radiologists will together examine the
MRI scans at baseline and week 24, without having
knowledge of the treatment group to which the patient/
participant belongs. The two radiologists will determine
by consensus for each study subject the numbers of new
and enhancing T2 lesions at week 24 weeks compared
with baseline, and thus the cumulative total number of
new lesions over the 24 week period. Mean and median
T2 and gadolinium enhancing lesions will be assessed for
each treatment allocation group at baseline and 24 weeks.
Rescue therapy
In the event of a relapse, the patient will undergo appro-
priate investigations and be commenced on steroid ther-
apy if appropriate. As these patients will then meet the
McDonald 2010 criteria [31] for diagnosis of MS, they
will be offered treatment in line with the current recom-
mendations for first-line treatment of RRMS. They will
be advised to continue study visits for the duration of
the trial.
Participants with CIS whose MRI scans show new le-
sions at the end of the study period (24 weeks) meeting
the McDonald 2010 criteria [31] for MS will also be of-
fered first-line therapy for RRMS, as is standard practice
in our institution.
Blinding
Patients, healthy control participants, and study staff, with
the exception of the hospital pharmacist and internal
monitor will remain blinded until the study database is
locked at the end of the trial. The study drug (Vigantol®)
and the placebo oil are identical in appearance, as is the
labeling and packaging. Each bottle will have a unique
four-digit product code, which has been generated by the
hospital pharmacist, and ranges from 1000 to 2499. These
numbers have been shuffled into random order, with the
first group of 750 numbers assigned to the active product
(Vigantol®) and the second group of 750 numbers to the
placebo oil. Participants will be dispensed two identical
bottles at 4-weekly intervals, which will be either two bot-
tles of the study drug (Vigantol®), two bottles of placebo
oil, or a bottle of each, equating to the two doses of vita-
min D and placebo being investigated in this study. Partic-
ipants will be advised to take a set dose from each bottle
per day. Mechanisms are in place so that the code can be
broken in the case of an emergency where it is essential
for the clinical management of the subject.
Sample size
The power calculations for this study were based on a
pilot study, which examined immunologic outcomes in
four healthy control participants treated with vitamin D
5,000 to 10,000 IU/day at our institution [32]. All calcu-
lations for numbers needed in the study were based on
α = 5% and β = 80%. Based on flow cytometry analysis
of T-cell subsets, the change in IL-17-producing CD4
T-cells (Th17 cells) had an effect size (mean ± SD) of
1.9 ± 1.8 indicating a need for five study subjects per
group for 80% power. For IFN-γ-producing CD4 T-cells
(Th1 cells), the effect size was 4.3 ± 6.3) indicating a
need for 19 subjects per group for 80% power. The
changes noted in cytokines in response to anti-CD3
stimulation of PBMC were 1) for IL-17, Δ = 44.5 ± 44.3,
thus 10 participants needed in each group; 2) for IFN-γ,
Δ = 32.8 ± 1.2, thus 6 needed in each group; and 3) for
IL-10, Δ = −455 ± 27, thus number needed is < 5. The
changes noted in cytokines in response to PPD stimula-
tion were 1) for IFN-γ, Δ = 1860 ± 1835, thus 10 needed,
in each group and 2) for IL-10, Δ = −576 ± 86, thus num-
ber needed is <5. On the basis of these results, at least 10
subjects should be included in each group (the only im-
munologic endpoint not powered would be the flow cy-
tometry analysis of the IFN-γ-producing cells). Recruiting
39 healthy controls and 45 patients with CIS will allow for
a drop-out rate of 20% and 30% respectively.
Statistical methods
All analyses assume a two-sided test of hypothesis with
an overall α level of 0.05. Immunologic endpoints and
post hoc analyses, which will include the 16 and 24 week
endpoints, are considered exploratory, and will not be
adjusted for multiple comparisons. Descriptive statistics
will be presented as mean ± SD. Non-parametric tests
will be used to compare characteristics between treatment
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groups. For outcomes, the sign/sign rank test will be used
to evaluate continuous outcomes. McNemar testing will
be used to categorize categorical and binary outcomes.
For non-parametric testing on unpaired continuous data,
the Wilcoxon rank sum test will be used. All outcomes
will be adjusted for baseline serum 25(OH)D levels, and
for mean serum levels achieved at weeks 16 and 24.
Missing data will be imputed as the mean of the pre-
ceding and following measurements. Only patients com-
pleting at least 4 months of full participation in the
study or experiencing a relapse at any time in the study
will be included in the final analysis. Non-adherent par-
ticipants, defined as those with an increase in serum
level of 25(OH)D of less than 50 nmol/l from baseline,
will be excluded from the final analysis.
Funding
The costs of conducting the clinical trial are funded by
the Department of Neurology, St Vincent’s University
Hospital.
Study sponsor
The trial sponsor is Dr Peter Doran, Senior Lecturer in
Medicine, University College Dublin, Dublin, Ireland.
Discussion
Supplemental vitamin D appears to have potential as a
therapeutic agent for MS; what is less clear is the opti-
mal dose of vitamin D needed to effect change within
the immune system. Our study is designed to address
this question, and to add to the growing evidence of the
safety and tolerability of high-dose vitamin D supplementa-
tion. As this is a phase II randomized, placebo-controlled
trial with two distinct study groups and is adequately
powered to meet the primary endpoint, it should be
considered a high-quality trial aiming to provide class II
evidence of the primary endpoint.
Existing guidelines on vitamin D supplementation are
conservative, and refer mainly to bone health [33], with
4,000 IU considered the upper limit of tolerability, des-
pite the fact that sun exposure can provide an adult with
up to 20,000 IU per day [34]. Older adults are now ad-
vised to sustain 25(OH) D concentrations of greater than
75 nmol/l for optimal bone health and, in order to achieve
that, they need to consume approximately 4,000 IU/day
of vitamin D [18,35]. Levels greater than 100 nmol/l are
needed to ensure that patients are receiving adequate
immunomodulating doses of vitamin D. Based on previ-
ous dosing studies [18], the maximum serum 25(OH)D
level expected with a daily dose of 10,000 IU is approxi-
mately 250 nmol/l, making both treatment doses safe
and tolerable.
The availability of DMT and the earlier recognition
and diagnosis of MS have a significant effect on trial
design for the evaluation of new drugs, and this also
raises ethical concerns. Most would feel that placebo-
controlled studies of the RRMS population are unethical.
This results in the need for large multicenter trials to
achieve adequate numbers to power the study over lon-
ger time periods to assess for clinical endpoints. Thus,
costs are generally prohibitive and really limits these
studies to large pharmaceutical companies.
In Ireland, the UK, Australia, and New Zealand, pa-
tients with CIS are treated conservatively until there
is evidence, on clinical or MRI grounds, of dissemin-
ation in time. Patients with CIS form a distinct population
with a well-established natural history, who are not ex-
posed to immunomodulatory therapy. Given the standard
practice in Ireland, there is no ethical concern with regard
to watchful withholding of treatment. Should patients
convert to RRMS during the trial, they will be offered
standard DMT. This study should add to the growing
evidence of the immunomodulatory effects of high-dose
supplemental vitamin D in demyelinating disease. We
hope to show that vitamin D is a safe and effective therapy
for patients with CIS.
Trial status
This trial is active and has been recruiting from November
2012.
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